101328-85-2

Usage

Chemical Properties

Pale Yellow Solid

Uses

A metabolite of Levosimendan

InChI:InChI=1/C11H13N3O/c1-7-6-10(15)13-14-11(7)8-2-4-9(12)5-3-8/h2-5,7H,6,12H2,1H3,(H,13,15)/t7-/m1/s1

Upstream product

• 132298-14-7 (R)-4-(4-Amino-phenyl)-3-methyl-4-oxo-butyric acid methyl ester 
• 139052-00-9 (R)-4-(4-Acetylamino-phenyl)-3-methyl-4-oxo-butyric acid 
• 139052-02-1 OR-1896 
• 616-02-4 citraconic acid anhydride 
• 139052-03-2 3-(p-Acetamidobenzoyl)-crotonsaeure 
• 81937-39-5 2-ethoxycarbonyl-3-(4-acetamidobenzoyl)butyric acid ethyl ester 
• 63514-63-6 N-(4-(2-bromopropionyl)phenyl)acetamide 
• 16960-49-9 N-(4-propionylphenyl)acetamide 
• 1260774-44-4 (-)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone di-p-anisoyl-D-tartrate 
• 50583-51-2 O,O′-di-p-anisoyl-D-tartaric acid 
• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 50583-51-2 (2R,3R)-2,3-bis[(4-methoxyphenyl)carbonyloxy]butanedioic acid 
• 101328-84-1 (5S)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one 
• 132298-10-3 N-[4-((R)-2-Chloro-propionyl)-phenyl]-acetamide 

Downstream Products

• 113118-40-4 (R)-5-methyl-6-[4-(4-oxo-1,4-dihydropyridin-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 101328-86-3 (R)-(-)-6-<4-(3-bromopropionamido)phenyl>-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 134052-12-3 2-{1,1-Dimethyl-2-[4-((R)-4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenylamino]-ethyl}-isoindole-1,3-dione 
• 134000-06-9 (R)-6-[4-(2-Amino-2-methyl-propylamino)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one 
• 107014-61-9 (R)-6-[4-(4-Oxo-2-imidazolin-2-ylamino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 141505-33-1 levosimendan 
• 1221499-63-3 (R)-(-)-6-[4-(2-pyridinylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-65-5 (R)-(-)-6-[4-(2-furanylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-60-0 C₁₈H₁₆ClN₃O 
• 1221499-56-4 C₁₈H₁₆N₄O₃ 
• 1221499-55-3 C₁₈H₁₆N₄O₃ 
• 1221499-61-1 C₂₁H₂₃N₃O₄ 
• 1221499-58-6 C₁₈H₁₇N₃O₂ 
• 1221499-59-7 C₁₈H₁₇N₃O₂ 

Relevant academic research and scientific papers

Preparation method of important intermediate of levosimendan

The invention belongs to the field, of synthesis of intermediates and relates to (R)- 6 - (4 -aminophenyl) - 5 - methyl - 444455-dihydropyridazine - 3333337. acetamide N - (4 - obtained by hydrolyzing)-methylpropionyl, phenyl, acetamide, in N - (4 - (3 - (-propionyl phenyl) - 2 - acetamide as starting material) and then chemical resolution.) yields high-purity,methylpropionyl (R)- N - (4 - (3 - (phenyl) - 2 - acetamide.). The present invention is very suitable for industrial production) by chemically resolving the high yield; dimethylamino,methylpropionyl-methaneanoyl-benzenesulfonamido (R)- N - (4 - (3 - phenylacetamido) obtained by hydrolyzing the intermediates with formaldehyde) dimethylamine. yields a high yield, yields a high yield of intermediate. The present invention relates to a, process for, producing high-chiral purified p-methyl propionylphenyl phenylacetonitrile.

DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS

Compounds of formula (I) which are nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and their use for the treatment of hyperproloferative diseases and/or disorders responsive to induction of cell death.

Synthesis and anti-congestive heart failure activity of novel levosimendan analogues

A series of levosimendan analogues were designed and synthesized, employing the Friedel-Crafts reaction, hydrolysis, and cyclization from the key intermediate compound R(-)-6-(4-aminophenyl)-5-methyl-4, 5-dihydro-3(2H)- pyridazinone, which was obtained from the starting material, acetanilide. These compounds, except 1b, exhibited potent anti-congestive heart failure activities, especially the compounds 1e and 1k, which showed more effective action than levosimendan. Springer Science+Business Media, LLC 2010.

PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS

In an embodiment, the present invention provides a process for preparing (-)-6-(4- aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of formula (Il) with a chiral tartaric acid derivative to obtain a diastereomeric salt of (-)-6-(4- aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone and the chiral tartaric acid derivative; and b) reacting the diastereomeric salt with a base to obtain (-)-6-(4- aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone. The (-)-6-(4-aminophenyl)-4,5- dihydro-5-methyl-3-(2H)-pyridazinone may be used to prepare levosimendan.

Studies on agents with vasodilator and β-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665

Synthesis of the four optical isomers of TZC-5665 (1), a candidate for the treatment of congestive heart failure, was achieved by the reaction of chiral diaminopyridazinone (2) with chiral glycidyl ether (3). The hypotensive and β-blocking activities of 1 and its optical isomers were examined when given intravenously into anesthetized rats. Furthermore these compounds were evaluated for inhibitory activity on cAMP phosphodiesterase III. Among the four optical isomers, R(A),S(B)-one (1c) possessed the essential activities of TZC-5665 (1).